Jan 22, 2018 10:51 JST
Source: Eisai
|
|
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
In Hepatocellular Carcinoma Based on Independent Imaging Review at ASCO-GI
TOKYO, Jan 22, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that the results of an analysis of a Phase III trial (REFLECT study / Study 304)(1) of its in-house discovered and developed anticancer agent lenvatinib mesylate versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma based on independent imaging review were presented(2) during the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) 2018, in San Francisco, the United States.
The presentation reported on an exploratory analysis of the secondary endpoints of Progression Free Survival (PFS), Time To Progression (TTP), and Objective Response Rate (ORR) in the REFLECT study based on blinded independent imaging review (IIR).
The IIR based on both RECIST (Response Evaluation Criteria in Solid Tumors) 1.1, which uses the traditional assessment of the effect on change in tumor diameter, and modified RECIST (mRECIST), which takes into account areas of tumor necrosis in addition to the RECIST 1.1 criteria, confirmed the investigators' findings of extensions in PFS and TTP as well as an increase in ORR compared to sorafenib (refer to the tables below) based on lenvatinib's superior reduction in tumor size. The results of the blinded IIR of the REFLECT study support the imaging findings of the clinical trial investigators.
In this study, the five most common adverse events observed in the lenvatinib arm were hypertension, diarrhea, decreased appetite, weight loss and fatigue, which is consistent with the known safety profile of lenvatinib.
Liver cancer is the second leading cause of cancer related deaths and is estimated to be responsible for 750,000 deaths per year globally.3 Additionally, 780,000 cases are newly diagnosed each year, about 80% of which occur in Asian regions, including Japan and China.(3)
Hepatocellular carcinoma accounts for 85% to 90% of primary liver cancer cases. Early stage hepatocellular carcinoma is treatable by a wide variety of means, including surgery, radiofrequency ablation, ethanol injection, and chemoembolization therapy, but treatment opinions for unresectable hepatocellular carcinoma are limited and the prognosis is very poor, meaning that this is an area of high unmet medical need.
Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017), China (October 2017), Taiwan (December 2017) and other countries. Eisai remains committed to generating scientific evidence aimed at maximizing the value of lenvatinib as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
About lenvatinib mesylate (generic name, "lenvatinib", product name: Lenvima / Kisplyx)
Discovered and developed in-house, lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor proliferation.
Currently, Eisai has obtained approval for lenvatinib as a treatment for refractory thyroid cancer in 50 countries, including the United States, Japan, in Europe and Asia under the brand name Lenvima. Additionally, Eisai has obtained approval for lenvatinib in combination with everolimus in the United States, Europe, and other countries, as a treatment for renal cell carcinoma (second-line). In Europe, lenvatinib was launched under the brand name Kisplyx for this indication. A Phase III study (Study 307) of lenvatinib in separate combinations with everolimus and pembrolizumab in renal cell carcinoma (first-line) is underway. A Phase Ib/II study to investigate the agent in combination with pembrolizumab in select solid tumors (non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, head and neck cancer, and melanoma) is underway. Additionally, a Phase Ib study of the agent in hepatocellular carcinoma is also underway.
About Study 304
Study 304 is a multicenter, randomized, open-label, global Phase III study comparing the efficacy and safety of lenvatinib versus sorafenib, a standard treatment for advanced hepatocellular carcinoma, as a first-line treatment for patients with unresectable hepatocellular carcinoma. In the study, 954 patients were randomized in a 1:1 ratio to receive lenvatinib 12 mg or 8 mg once a day, depending on baseline body weight (n= 478) or sorafenib 400 mg twice a day (n= 476). Treatment was continued until disease progression or unacceptable toxicity. The primary endpoint of the study was Overall Survival (OS), with the goal of demonstrating non-inferiority. Other factors including PSF, TTP, ORR and Quality of Life (QOL) were assessed as secondary endpoints. In this study, the five most common adverse events observed in the lenvatinib arm were hypertension, diarrhea, decreased appetite, weight loss and fatigue, which is consistent with the known side-effect profile of lenvatinib.
About the Independent Imaging Review and the Clinical Trial Investigators' Review
In order to preserve the uniformity of imaging assessment, an independent imaging review is conducted by a testing organization (central testing laboratory) which is independent of the medical organizations conducting the clinical trial. The clinical trial investigators' review is a review by the physician in charge of the clinical trial at each medical organization according to specific criteria (such as RECIST).
About RECIST (Response Evaluation Criteria In Solid Tumors)
RECIST1.1 is a set of assessment criteria used to evaluate effects on solid cancers (based on changes in tumor diameter). mRECIST is a new criteria that takes into account areas of tumor necrosis in addition to RECIST1.1.
About Progression Free Survival (PFS), Time to Progression (TTP) and Objective Response Rate (ORR)
PFS is the time from the date of randomization to the date of disease progression, or date of death from any cause, whichever occurs first. TTP is the time until the date of disease progression, and is different to PFS in that it does not consider death from any cause. ORR is the combined proportion of patients whose tumor was eliminated (complete response) and whose tumor was reduced by over 30% in size (partial response).
(1) A. Cheng et al. "Phase 3 trial of lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma", the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), (June 2017), Abstract No: 4001 (2) Lencioni R, et al. "Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)," ASCO-GI 2018, Abstract #345 (3) GLOBOCAN2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/
Contact:Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date Apr 24, 2024 17:19 JST
| MC and Denka Sign J/V Agreement in Fullerene Business Apr 24, 2024 17:02 JST
| Mitsubishi Motors Posts Record Sales in the Philippines in FY2023 Apr 24, 2024 13:56 JST
| NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance Apr 24, 2024 13:25 JST
| Fujitsu SX Survey reveals key success factors for sustainability Apr 23, 2024 10:25 JST
| Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions Apr 22, 2024 16:09 JST
| NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II Apr 22, 2024 15:09 JST
| Soft Space Launches the First and Only JCB Payment Gateway in Malaysia Apr 22, 2024 15:00 JST
| TOYOTA GAZOO Racing takes a one-two in Croatian thriller Apr 22, 2024 10:47 JST
| First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
| Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan Apr 18, 2024 11:14 JST
| Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Apr 18, 2024 10:53 JST
| All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating Apr 18, 2024 09:22 JST
| Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan Apr 17, 2024 16:17 JST
| Honda Unveils Next-generation EV Series for China Apr 17, 2024 12:15 JST
| Lexus presents Time at the 2024 Milan Design Week Apr 16, 2024 18:49 JST
| Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA Apr 16, 2024 14:36 JST
|
More Latest Release >>
|